Latest Information Update: 28 Jun 2002
At a glance
- Originator Psoraya Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 12 May 2000 New profile
- 12 May 2000 Investigation in Psoriasis in USA (Topical)